Is non-HDL as good as ApoB?
Close, and it costs nothing extra. Non-HDL is your total cholesterol minus your HDL, worked out from the panel you already have. The 2026 US guideline says it “correlates well” with ApoB and disagrees with it less than LDL does, and it prefers either one over LDL when triglycerides are 150 or more. When non-HDL and ApoB do split, ApoB is the better guide.
What we’d do
If all you have is a standard panel, look at non-HDL before LDL. Then get ApoB at least once, above all if your triglycerides are high, you have diabetes, or you’re on treatment and at your LDL goal. If your ApoB and non-HDL agree, non-HDL can keep watch between ApoB tests.
What each one measures
Non-HDL adds up the cholesterol in every particle that can build plaque, the LDL plus the triglyceride-rich ones. ApoB counts those same particles, one protein on each. With trucks on a road, non-HDL weighs all the cargo and ApoB counts the trucks.
That’s why the two usually agree. In UK Biobank’s 293,876 adults, ApoB and non-HDL were correlated at 0.96, a very close match. But a tight line across a whole country still leaves room for one person to sit well off it.
At the same non-HDL of 160, ApoB ran from 88 to 112.
That range held 95 of 100 people in UK Biobank. Over 10 years, about 6.4 in 100 of those with a high ApoB for their non-HDL had a heart attack, stroke or similar event, against 4.6 in 100 with a low one.
When they disagree, which wins
In UK Biobank, Marston and colleagues put ApoB, non-HDL and triglycerides into one model for 389,529 people not on cholesterol medicine. On its own each one was tied to heart attacks. Together, only ApoB stayed tied to them.
The Copenhagen study of 13,015 statin users is more mixed. High ApoB with a low non-HDL came with 1.21 times the deaths from any cause, but not with more heart attacks (0.93, which could be chance). For most people non-HDL tells the same story, and ApoB adds the most in the cases where the two split.
The goals line up
The National Lipid Association matched the three numbers to the same goals in the 2026 guideline.
| Risk | Non-HDL goal | ApoB goal |
|---|---|---|
| Very high | under 85 | under 60 |
| High | under 100 | under 70 |
| Borderline or intermediate | under 130 | under 90 |
cholesterol.guide works out your non-HDL from your panel. To see whether your ApoB and LDL agree, use Do my ApoB and LDL agree?.
6 sources
- Blumenthal RS, Morris PB, Gaudino M and others, 2026 ACC/AHA guideline on the management of dyslipidemia, JACC, 2026doi.org
- The same guideline, full text, Circulation, 2026api.iscpcardio.org
- Sniderman AD and others, Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention, European Heart Journal, 2024pmc.ncbi.nlm.nih.gov
- Marston NA and others, Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis, JAMA Cardiology, 2022pubmed.ncbi.nlm.nih.gov
- Johannesen CDL and others, Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients, Journal of the American College of Cardiology, 2021pubmed.ncbi.nlm.nih.gov
- Soffer DE, Marston NA, Maki KC and others, Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association, Journal of Clinical Lipidology, 2024pmc.ncbi.nlm.nih.gov
